Skip to content

Released Aug 10, 2015, after the close

10-Q filed Aug 10, 2015, 41 days after period end · 0001144204-15-047801

Q2 2015 · 10-Q
Revenue$1.34M−44.9% vs Q2 2014−21.0% vs Q1 2015
Net Income-$5.07MN/M vs Q2 2014N/M vs Q1 2015
EPS Diluted-$0.05N/M vs Q2 2014N/M vs Q1 2015
Gross Profit$1,111,000+2.8%
Operating Income-$5,584,000N/M
Operating Cash Flowderived-$5,346,000N/M
Free Cash Flowderived-$5,579,000N/M
Margins · derived
Gross margin83.2%+38.6 pt vs Q2 2014
Operating margin-418.0%−193.3 pt vs Q2 2014
Net margin-379.6%−127.2 pt vs Q2 2014

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2015Q2 2014Q2 2013Q2 2012
Revenue$1.34M$2.43M$2.26M$26.11M
Net Income-$5.07M-$6.12M-$6.84M$9.64M
EPS Diluted-$0.05-$0.07-$0.07$0.10

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR